N-(2-fluoro-5-(1-methyl-6-oxo-5-(4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-ylamino)-1,6-dihydropyridazin-3-yl)phenyl)-5,6,7,8-tetrahydroindolizine-2-carboxamide | 1227208-34-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-fluoro-5-(1-methyl-6-oxo-5-(4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-ylamino)-1,6-dihydropyridazin-3-yl)phenyl)-5,6,7,8-tetrahydroindolizine-2-carboxamide
• 英文别名: N-[2-fluoro-5-[1-methyl-6-oxo-5-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridazin-3-yl]phenyl]-5,6,7,8-tetrahydroindolizine-2-carboxamide
• CAS: 1227208-34-5
• 化学式: C₂₆H₂₇FN₈O₂
• 分子量: 502.551
• InChiKey: VHKYYBAVPIGVCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS<br/>[FR] PYRIDAZINONES ET LEUR UTILISATION COMME INHIBITEURS DE LA BTK
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2010056875A1

  公开（公告）日：2010-05-20

  Compounds of Formula (I) that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula (I), together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了抑制Btk的化合物(I)。描述了包含至少一种化合物(I)的药物组合物，以及至少一种从载体、辅料和赋形剂中选择的药用可接受载体。描述了治疗对Btk活性和/或B细胞活性抑制敏感的患者的方法。描述了检测样品中Btk存在的方法。
• PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：Barbosa JR. Antonio J.M.

  公开号：US20110301145A1

  公开（公告）日：2011-12-08

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了化学式I的化合物，其能够抑制Btk。本文还描述了包含至少一种化学式I化合物的制药组合物，以及至少选择自载体、佐剂和赋形剂中的一种药学可接受载体的制药组合物。本文还描述了治疗对Btk活性和/或B细胞活性抑制有响应的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。
• PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS
  申请人：Gilead Connecticut, Inc.

  公开号：EP2365970B1

  公开（公告）日：2018-03-21
• Pyridazinones and their use as btk inhibitors
  申请人：CGI Pharmaceuticals, Inc.

  公开号：EP2365970A1

  公开（公告）日：2011-09-21
• US8598174B2
  申请人：——

  公开号：US8598174B2

  公开（公告）日：2013-12-03